This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Diagnosing testosterone deficiency (TD)

Starting the conversation with your patients

Identifying at-risk patients

Guidelines from the International Society for the Study of the Ageing Male (ISSAM) Hypogonadism panel recommend the investigation of TD in men with the following conditions:2

Illustration of a man with pointers to different parts of the body and text describing the psychological, medication, physical, cardiovascular health, metabolism and sexual function conditions in men that warrant investigation of TD.

The British Society for Sexual Medicine (BSSM) guidelines for UK practice suggest screening for TD in men presenting with:3

  • Consistent and multiple signs of TD
  • Erectile dysfunction, loss of spontaneous erections or low sexual desire
  • T2DM, BMI >30 kg/m2 or waist circumference >102 cm (40.2 inches)
  • Long-term use of opiate, antipsychotic or anticonvulsant medication

References

  1. Khera M, Adaikan G, Buvat J, et al. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(12):1787–1804.
  2. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.
  3. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.

TES/2022/045. February 2023.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com

Where next...